The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of biweekly carboplatin and paclitaxel as first-line treatment for elderly patients with advanced non-small cell lung cancer.
H. Terai
No relevant relationships to disclose
K. Soejima
No relevant relationships to disclose
M. Nakamura
No relevant relationships to disclose
K. Naoki
No relevant relationships to disclose
H. Yasuda
No relevant relationships to disclose
R. Satomi
No relevant relationships to disclose
S. Nakayama
No relevant relationships to disclose
S. Yoda
No relevant relationships to disclose
S. Ikemura
No relevant relationships to disclose
T. Sato
No relevant relationships to disclose
K. Asano
No relevant relationships to disclose